Please assess the completion status of the following clinical trial:

Trial Title: Subcutaneous Bupivacaine Decrease Post-op Pain in Patients Undergoing C-Section

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~* elective cesarean delivery~* planned spinal anesthesia~Exclusion criteria:~* Non-English speaking~* Urgent or emergent cesarean delivery~* Active labor \[defined as: \>4cm cervical dilation or regular contractions noted on tocometer (\>2 contractions in a 10 minute period for 30 consecutive minutes)\]~* Chronic antepartum opioid use~* History of substance abuse (alcohol or drug)~* Current tobacco use~* Chronic steroid use

- Gender: FEMALE
- Minimum Age: 17 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- bupivacaine 0.25% (Type: ACTIVE_COMPARATOR): standard intrathecal bupivacaine (Marcaine) 0.75% 1.5-1.7 ml, intrathecal morphine (Duramorph) 150mcg plus intrathecal fentanyl 10 mcg + 20 ml subcutaneous bupivacaine (Marcaine) 0.25%
- bupivacaine 0.25% + epinephrine (Type: ACTIVE_COMPARATOR): standard intrathecal bupivacaine (Marcaine) 0.75% 1.5-1.7 ml, intrathecal morphine (Duramorph) 150mcg plus intrathecal fentanyl 10 mcg + 20 ml subcutaneous bupivacaine (Marcaine) 0.25% with Epinephrine
- Saline Solution (Type: PLACEBO_COMPARATOR): standard intrathecal bupivacaine (Marcaine) 0.75% 1.5-1.7 ml, intrathecal morphine (Duramorph) 150mcg plus intrathecal fentanyl 10 mcg + 20 ml subcutaneous NACL 0.9% (placebo)

Based on this trial design, predict the completion outcome and termination type (if applicable).